The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

sonderdruck aus: BMC Cancer | 2015

von Greve, G. | Schiffmann, I. | Pfeifer, D. | +3